VISIUM TECHNOLOGIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VISIUM TECHNOLOGIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $0 | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | $0 | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | $0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $0 | Oct 6, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | $0 | Oct 4, 2022 |
| FY2022 | Jun 30, 2021 | $25.0K | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | $0 | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $0 | Oct 9, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.34M) | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | ($2.88M) | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | ($3.31M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($5.19M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | ($3.37M) | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | ($1.54M) | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($1.76M) | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | ($1.39M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($1.76M) | Aug 20, 2018 |
| FY2017 | Jun 30, 2016 | $634.1K | Sep 28, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.65M) | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | ($2.59M) | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | ($2.41M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($4.68M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | ($4.11M) | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | ($953.5K) | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($2.86M) | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | ($1.04M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($2.06M) | Aug 20, 2018 |
| FY2017 | Jun 30, 2016 | ($719.9K) | Sep 28, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $325 | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | $86.7K | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | $215.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $361.3K | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | $258.2K | Oct 4, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.65M | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | $2.50M | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | $2.20M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $4.32M | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | $3.88M | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | $918.0K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $2.72M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $1.04M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $2.06M | Aug 20, 2018 |
| FY2017 | Jun 30, 2016 | $719.9K | Sep 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($411.2K) | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | ($488.3K) | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | ($523.9K) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($2.22M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | ($792.6K) | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | ($106.8K) | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($566.7K) | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | ($59.4K) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($279.0K) | Aug 20, 2018 |
| FY2017 | Jun 30, 2016 | $424.3K | Sep 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $67.6K | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | $8.5K | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | $10.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $137.0K | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | $180.6K | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | $30.3K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $18.7K | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $11.4K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $2.3K | Aug 20, 2018 |
| FY2017 | Jun 30, 2016 | $1.8K | Sep 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Jun 30, 2013 | $1.90M | Sep 1, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($5.84M) | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | ($5.15M) | Oct 7, 2025 |
| FY2025 | Jun 30, 2023 | ($4.25M) | Oct 7, 2025 |
| FY2024 | Jun 30, 2022 | ($2.79M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2021 | ($2.84M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2020 | ($3.38M) | Oct 4, 2022 |
| FY2020 | Jun 30, 2019 | ($3.24M) | Oct 9, 2020 |
| FY2020 | Jun 30, 2018 | ($4.51M) | Oct 9, 2020 |
| FY2019 | Jun 30, 2017 | ($4.93M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2016 | ($4.50M) | Aug 20, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($64.09M) | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | ($62.75M) | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | ($59.87M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($56.56M) | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | ($51.37M) | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | ($47.99M) | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($46.45M) | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | ($44.69M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($43.30M) | Aug 20, 2018 |
| FY2017 | Jun 30, 2016 | ($41.54M) | Sep 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $10.0K | Oct 6, 2023 |
| FY2023 | Jun 30, 2022 | $137.0K | Oct 6, 2023 |
| FY2021 | Jun 30, 2021 | $125.2K | Oct 13, 2021 |
| FY2021 | Jun 30, 2020 | $30.3K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $18.7K | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $11.4K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $2.3K | Aug 20, 2018 |
| FY2018 | Jun 30, 2016 | $1.8K | Aug 20, 2018 |
| FY2017 | Jun 30, 2015 | $6.1K | Sep 28, 2017 |
| FY2016 | Jun 30, 2014 | $65 | Oct 14, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | 0 | Sep 28, 2017 |
| FY2017 | Jun 30, 2016 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Oct 14, 2016 |
| FY2013 | Jun 30, 2013 | 0 | Sep 1, 2015 |
| FY2013 | Jun 30, 2012 | 0 | Sep 1, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Oct 7, 2025 |
| FY2017 | Jun 30, 2017 | 0 | Sep 28, 2017 |
| FY2017 | Jun 30, 2016 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Oct 14, 2016 |
| FY2013 | Jun 30, 2013 | 0 | Sep 1, 2015 |
| FY2013 | Jun 30, 2012 | 0 | Sep 1, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 368.54M | Oct 7, 2025 |
| FY2025 | Jun 30, 2024 | 213.95M | Oct 7, 2025 |
| FY2024 | Jun 30, 2023 | 29.84M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 2.90M | Oct 6, 2023 |
| FY2022 | Jun 30, 2021 | 2.18M | Oct 4, 2022 |
| FY2021 | Jun 30, 2020 | 1.54B | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | 42.07M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | 9.38M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | 499,152 | Aug 20, 2018 |
| FY2017 | Jun 30, 2016 | 5.65M | Sep 28, 2017 |